PDNO / Attgeno - LARVOL DELTA

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Attgeno AB | N=16 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Attgeno AB | Trial completion date: Apr 2023 ➔ Dec 2023 | Trial primary completion date: Apr 2023 ➔ Dec 2023

Surgery • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Attgeno AB

New P2 trial • Surgery • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension (clinicaltrials.gov) - P1/2 | N=16 | Recruiting | Sponsor: Attgeno AB | Trial completion date: Aug 2022 ➔ May 2023 | Trial primary completion date: Jul 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A First-in-human Study to Assess the Safety and Tolerability of PDNO (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: Attgeno AB | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A First-in-human Study to Assess the Safety and Tolerability of PDNO (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Attgeno AB | Trial completion date: Dec 2021 ➔ Jul 2022 | Trial primary completion date: Nov 2021 ➔ May 2022

Trial completion date • Trial primary completion date • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH (clinicaltrials.gov) - P1/2 | N=16 | Recruiting | Sponsor: Attgeno AB | Trial completion date: Aug 2021 ➔ Aug 2022 | Trial primary completion date: Jul 2021 ➔ Jul 2022

Trial completion date • Trial primary completion date • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH (clinicaltrials.gov) - P1/2; N=16; Recruiting; Sponsor: Attgeno AB; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A First-in-human Study to Assess the Safety and Tolerability of PDNO (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Attgeno AB

Clinical • New P1 trial • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases